Skip to Main Content

In a sobering report, the World Health Organization concluded that pricing for cancer medicines is “impairing” the ability of governments to provide affordable treatments and recommended a host of potential measures for widening access, such as greater transparency about discounts and R&D costs, differential pricing among countries, and short-term price caps, among other things.

The report, which was issued on the eve of a WHO board meeting, concluded that the “market structure of cancer medicines is characterized by imperfect competition” and there is evidence that individual companies hold a monopoly over specific categories of treatments. The analysis found just three companies accounted for about half of the global market for cancer medicines, based on 2017 sales.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.